{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:13:41Z","timestamp":1785190421178,"version":"3.55.0"},"reference-count":26,"publisher":"VM Media SP. zo.o VM Group SK","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","oncology-and-radiotherapy.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reports of Practical Oncology &amp; Radiotherapy"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.rpor.2016.10.005","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T11:32:52Z","timestamp":1480073572000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel Disease"],"prefix":"10.5603","volume":"22","author":[{"given":"Matthew M.","family":"Gestaut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3595","reference":[{"key":"10.1016\/j.rpor.2016.10.005_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(01)00002-4","article-title":"Epidemiology of inflammatory bowel disease","volume":"31","author":"Loftus","year":"2010","journal-title":"Gastroenterol Clin N Am"},{"key":"10.1016\/j.rpor.2016.10.005_bib0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004836-199201000-00005","article-title":"Quality of life in inflammatory bowel disease","volume":"14","author":"Love","year":"1992","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.rpor.2016.10.005_bib0155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rpor.2016.10.005_bib0160","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rpor.2016.10.005_bib0165","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.rpor.2016.10.005_bib0170","first-page":"57","article-title":"Chronic inflammatory bowel disease and cancer","volume":"47","author":"Pohl","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.rpor.2016.10.005_bib0175","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1200\/JCO.1996.14.7.2043","article-title":"Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy","volume":"14","author":"Tiersten","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpor.2016.10.005_bib0180","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0360-3016(99)00374-0","article-title":"Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms","volume":"46","author":"Willett","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rpor.2016.10.005_bib0185","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/014107688307600606","article-title":"Bowel disease after radiotherapy","volume":"76","author":"Schofield","year":"1983","journal-title":"J R Soc Med"},{"key":"10.1016\/j.rpor.2016.10.005_bib0190","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/00007611-198907000-00027","article-title":"Early cervical cancer coexistent with idiopathic inflammatory bowel disease","volume":"82","author":"Hoffman","year":"1989","journal-title":"South Med J"},{"key":"10.1016\/j.rpor.2016.10.005_bib0195","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.prro.2014.09.004","article-title":"Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: patient selection and dosimetric parameters with modern treatment techniques","volume":"5","author":"Murphy","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.rpor.2016.10.005_bib0200","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brachy.2012.04.008","article-title":"Toxicity after 125 I prostate brachytherapy in patients with inflammatory bowel disease","volume":"12","author":"Pai","year":"2013","journal-title":"Brachytherapy"},{"key":"10.1016\/j.rpor.2016.10.005_bib0205","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0360-3016(01)01629-7","article-title":"Acute and late radiotherapy toxicity in patients with inflammatory bowel disease","volume":"51","author":"Song","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rpor.2016.10.005_bib0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rpor.2016.10.005_bib0215","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/american college of radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpor.2016.10.005_bib0220","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.rpor.2016.10.005_bib0225","doi-asserted-by":"crossref","first-page":"224","DOI":"10.6004\/jnccn.2004.0021","article-title":"Prostate cancer. NCCN clinical practice guidelines in oncology","volume":"2","year":"2004","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.rpor.2016.10.005_bib0240","series-title":"Common terminology criteria for adverse events (CTCAE) version 4.0","first-page":"4","year":"2009"},{"key":"10.1016\/j.rpor.2016.10.005_bib0245","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/09553000210137671","article-title":"Anti-inflammatory effect of low-dose X-irradiation and the involvement of a TGF-\u03b2 1-induced down-regulation of leukocyte\/endothelial cell adhesion","volume":"78","author":"Roedel","year":"2002","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.rpor.2016.10.005_bib0250","first-page":"1","article-title":"Therapeutic effects of low radiation doses","volume":"170","author":"Trott","year":"1994","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft"},{"key":"10.1016\/j.rpor.2016.10.005_bib0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0167-8140(99)00066-3","article-title":"Radiobiological mechanisms of anti-inflammatory radiotherapy","volume":"51","author":"Trott","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.rpor.2016.10.005_bib0260","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0167-8140(99)00100-0","article-title":"Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer","volume":"55","author":"Zelefsky","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.rpor.2016.10.005_bib0265","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0360-3016(02)02857-2","article-title":"High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients","volume":"53","author":"Zelefsky","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rpor.2016.10.005_bib0270","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.rpor.2013.05.006","article-title":"Late rectal and bladder toxicity following radiation therapy for prostate cancer: predictive factors and treatment results","volume":"18","author":"Fuentes-Raspall","year":"2013","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.rpor.2016.10.005_bib0275","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.rpor.2013.09.007","article-title":"Toxicity outcome in patients treated with modulated arc radiotherapy for localized prostate cancer","volume":"19","author":"Lengua","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.rpor.2016.10.005_bib0280","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rpor.2016.01.005","article-title":"Reducing radiation-associated toxicity using online image guidance (IGRT) in prostate cancer patients undergoing dose-escalated radiation therapy","volume":"21","author":"Becker-Schiebe","year":"2016","journal-title":"Rep Pract Oncol Radiother"}],"container-title":["Reports of Practical Oncology &amp; Radiotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1507136716301481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1507136716301481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T14:14:14Z","timestamp":1613657654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1507136716301481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1507136716301481"],"URL":"https:\/\/doi.org\/10.1016\/j.rpor.2016.10.005","relation":{},"ISSN":["1507-1367"],"issn-type":[{"value":"1507-1367","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Reports of Practical Oncology & Radiotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpor.2016.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o.","name":"copyright","label":"Copyright"}]}}